Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C22H19NO8 and a molecular weight of approximately 425.39 g/mol[1][2][4]. It is known by several code names, including IX1 and CHEMBL184444. The structure features an isoxazole core substituted with phenolic and methoxycarbonyl groups. It has been cataloged in chemical databases such as PubChem (CID: 449162), DrugBank (DB08001), and ChemSpider (ID: 395769). There is no evidence that this compound has reached clinical development or approval; it appears to be an experimental or screening molecule, possibly used in biochemical assays or structural studies[2][7]. No specific mechanism of action, biological target, or therapeutic indication has been reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(3-{3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]propenyl}phenyl)-4-(hydroxymethyl)isoxazole-3-carboxylic acid.